Literature DB >> 23255242

Major adverse cardiovascular events and mortality in systemic lupus erythematosus patients after successful delivery: a population-based study.

Lung-Sheng Wu1, Chao-Hsiun Tang, Yu-Sheng Lin, Chia-Pin Lin, Sheng-Tzu Hung, Hsiao-Lin Hwa, Shue-Fen Luo, Pao-Hsien Chu.   

Abstract

BACKGROUND: Limited data exist regarding the incidence rate and hazard ratios (HRs) of major adverse cardiovascular events and mortality in the successful-delivery women with or without systemic lupus erythematosus.
METHODS: A retrospective, population-based cohort study was performed on 1,132,089 parturients from 1999 to 2003. The Kaplan-Meier method and the log-rank test were used to examine the effect of systemic lupus erythematosus on the incidence of major adverse cardiovascular events and mortality. Cox-proportional hazard regression modeling was used to determine the adjusted HRs of systemic lupus erythematosus on the risk of major adverse cardiovascular events and mortality among successful-delivery women.
RESULTS: Systemic lupus erythematosus group has the highest risk for major adverse cardiovascular events and mortality. The incidence rate of major adverse cardiovascular events and all-causes mortality among lupus women was 194.67 and 438.82 per 100,000 patients per year, respectively. Lupus women had higher incidence rates of major adverse cardiovascular events, including myocardial infarction, (HR, 54.43; confidence interval [CI], 16.04-184.78; P < 0.0001), heart failure (HR, 11.10; CI, 2.71-45.52; P < 0.0001), percutaneous coronary intervention (HR, 228.32; CI, 43.34-1203.00; P < 0.0001), stroke (HR, 8.02; CI, 3.79-16.99; P < 0.0001) and maternal death (HR, 11.68; CI, 7.97-17.10; P < 0.0001).
CONCLUSIONS: Although major adverse cardiovascular events and mortality are rare events in women of reproductive age, the incidence rates have increased approximately 10-fold among lupus women with successful delivery. Clinicians should note the possibility of persisting major adverse cardiovascular events and death in young women with lupus and successful delivery.

Entities:  

Mesh:

Year:  2014        PMID: 23255242     DOI: 10.1097/MAJ.0b013e318278707f

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  6 in total

Review 1.  The Application and Future of Big Database Studies in Cardiology: A Single-Center Experience.

Authors:  Kuang-Tso Lee; Ai-Ling Hour; Ben-Chang Shia; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2017-11       Impact factor: 2.672

2.  Maternal-placental syndrome and future risk of accelerated cardiovascular events in Parous Swedish women with systemic lupus erythematosus - a population-based retrospective cohort study with time-to-event analysis.

Authors:  May Ching Soh; Fadia Dib; Catherine Nelson-Piercy; Magnus Westgren; Lesley McCowan; Dharmintra Pasupathy
Journal:  Rheumatology (Oxford)       Date:  2016-03-25       Impact factor: 7.580

3.  Maternal Hypertensive Disorders in Pregnant Women With Systemic Lupus Erythematosus and Future Cardiovascular Outcomes.

Authors:  Julia F Simard; Marios Rossides; Elizabeth V Arkema; Elisabet Svenungsson; Anna-Karin Wikström; Murray A Mittleman; Jane E Salmon
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-04       Impact factor: 5.178

4.  Newly diagnosed atrial fibrillation is an independent factor for future major adverse cardiovascular events.

Authors:  Chen-Yu Li; Chia-Pin Lin; Yu-Sheng Lin; Lung-Sheng Wu; Chee-Jen Chang; Pao-Hsien Chu
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

5.  Major Adverse Cardiovascular Events in Treated Periodontitis: A Population-Based Follow-Up Study from Taiwan.

Authors:  Shing-Hsien Chou; Ying-Chang Tung; Yu-Sheng Lin; Lung-Sheng Wu; Chia-Pin Lin; Eric Jein-Wein Liou; Chee-Jen Chang; Suefang Kung; Pao-Hsien Chu
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

6.  Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.

Authors:  Fu-Chih Hsiao; Ying-Chang Tung; Shing-Hsien Chou; Lung-Sheng Wu; Chia-Pin Lin; Chun-Li Wang; Yu-Sheng Lin; Chee-Jen Chang; Pao-Hsien Chu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.